The World Health Organization (WHO) disclosed on February 10, 2026, that 50% of the 1.2 billion people living with cataract-induced blindness lack access to surgery, a $0.80-to-$45 procedure that restores sight in 20 minutes. The report, published under the banner of the UN’s Sustainable Development Goals, underscores a paradox: the most effective treatment for avoidable blindness is simultaneously the most neglected.
Cataract surgery is the single most cost-effective public health intervention identified by the Institute for Health Metrics and Evaluation since 1990. Yet 86% of those needing care live in low- and middle-income countries where surgical density per 100,000 capita is 0.6 procedures—compared to 300 in high-income nations. The gap is not a failure of medical science but of resource allocation.
The WHO identifies systemic bottlenecks: 70% of rural cataract patients lack access to even a basic surgical center; 40% of ophthalmologists in sub-Saharan Africa work in urban private clinics. Governments like India, where 12.4 million cataract surgeries are annual, still fail to universalize coverage beyond state-run hubs. Nigeria’s Ministry of Health reports 68 districts with no functional eye care infrastructure.
What the report obscures are the geopolitical dimensions. Cataract surgery supply chains depend on 92% of disposable phaco systems being produced by three firms in the U.S. and Germany. A $2500 machine that costs $0.73 to operate in Dubai sells at $300 in Ethiopia due to patent protections. This pricing model ensures profitability for manufacturers but traps patients in cycles of debt.
The largest oversight in WHO’s framing is the exclusion of community health worker programs. Rwanda’s 2018 “Vision 2020” initiative, which trained 1,200 village nurses to triage cataract patients pre-surgery, reduced blindness by 34% in 5 years. Why no similar models in Nigeria or Indonesia? The WHO’s centralization of surgical delivery ignores local solutions that cost 63% less than hospital-based care.
Future WHO campaigns must tie funding to decentralized networks. The World Bank’s 2024 Healthcare Infrastructure Bond, which allocated $7.8 billion for African surgical centers, could be redirected toward community-level training. Conversely, multinational device companies, shielded by intellectual property laws, will continue extracting rents unless pressured to license technology to local manufacturers.
The next UN Global Health Summit on September 20, 2026, is a pivot point. If member states fail to mandate patent overrides for cataract surgery tools, the WHO’s 2030 target of a 90% reduction in preventable blindness will remain unattainable. Progress will hang on whether governments treat sight as a human right or a commodity.